Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. were down after-hours Thursday after a new study found an increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications. The Wall Street Journal reported late Thursday the outcome of the trial, presented by researchers at the annual scientific meeting of the Heart Rhythm Society in Boston, raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. The procedure, meant to stop abnormal electrical signals from causing irregular heartbeats, involves a doctor inserting a thin tube through a patient’s blood vessels to deliver tiny scars to heart tissue. Shares of Abbott Laboratories, which makes the device used in the procedure, fell 1.5% to $59.67.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.